Retinoids are proposed chemopreventive agents that inhibit cell proliferation and induce differentiation. Their ability to prevent azoxymethane (AOM)-induced aberrant crypt foci (ACF) and tumors and to modulate cell proliferation was investigated in the colon of male F344 rats. Thirteen retinoids were evaluated for prevention of ACF and two of them, 9-cis-retinoic acid (RA) and 4-(hydroxyphenyl)retinamide (4-HPR), were also evaluated for prevention of colon cancer. The retinoids were administered continuously in the diet starting 1 week prior to the first of two weekly 15 mg/kg i.p. injections of AOM and for a total of either 5 or 36 weeks in order to evaluate their effect on colonic ACF and tumors. At a concentration of 1 mmol/kg diet, 2-(carboxyphenyl)retinamide caused the greatest reduction (57.7%) in the yield of ACF. 9-cis-RA was toxic at 1 mmol/ kg so that it was evaluated at 0.1 mmol/kg, resulting in a 41.6% reduction in ACF. The ability of the retinoids to reduce the proliferating cell nuclear antigen (PCNA) labeling index in ACF and in non-involved crypts correlated with their ability to prevent ACF. Both 9-cis-RA (0.1 and 0.2 mmol/kg diet) and 4-HPR (1 and 2 mmol/kg diet) were highly effective in decreasing the yield of AOM-induced colon tumors. In summary, retinoids were demonstrated to reduce cell proliferation and to prevent ACF and tumors in the colon, suggesting promise as preventive agents for colon cancer.
Introduction
Colon cancer continues to be a leading cause of mortality in the USA. Chemopreventive agents are being developed in an effort to prevent the occurrence of this common disease. Retinoids, both natural and synthetic vitamin A derivatives, are candidates for use in cancer chemoprevention (1) (2) (3) (4) . The retinoids have proven to be effective in inducing cellular differentiation and suppressing proliferation in numerous tumor cell lines, including lines derived from colon cancer (5, 6) . Epidemiological studies have suggested an inverse correlation between the development of cancer and the dietary consumption of vitamin A or β-carotene (7) . Recently retinoids such as all-trans retinoic acid (RA*) have indicated efficacy for treating acute promyelocytic leukemia (8, 9) and for preventing premalignant oral lesions (1) and second primary tumors of head and neck cancers (1, 10) . Previous studies of cancer prevention in animals with retinoids have indicated prevention of cancer of colon, liver, lung, mammary gland, prostate and skin (11) (12) (13) (14) (15) (16) . Furthermore, these studies demonstrated the need to develop other retinoids with greater efficacy and less toxicity.
The azoxymethane (AOM)-induced colon tumor model in rats results in adenomas and adenocarcinomas which contain certain of the molecular characteristics observed in human tumors, e.g. mutations in the K-ras oncogene (4) . This model has been employed to examine a wide range of potential chemopreventive agents, including non-steroidal anti-inflammatory drugs and α-difluoromethylornithine (4). We therefore used the AOM-induced colon tumor model to evaluate two retinoids, 9-cis-RA and 4-(hydroxyphenyl)retinamide (4-HPR), for their ability to prevent colon cancer.
Aberrant crypt foci (ACF) are putative precancerous lesions that are induced by AOM and other carcinogens in the colon of rats and mice (17) (18) (19) (20) (21) (22) (23) (24) (25) and have been found in the colon of humans (26, 27) . ACF are hyperproliferative lesions with other characteristics in common with colon tumors, as reviewed by Bird (17) . Pretlow et al. (18) have shown that ACF have an increased proliferative activity relative to adjacent normal crypts, which was comparable with that found in adenomas and adenocarcinomas of the colon in rats. Prevention of ACF in rats has been used to screen agents for chemopreventive activity in the colon (20) (21) (22) (23) . Although only a limited number of agents have been evaluated so far, there appears to be a relatively good correlation between the prevention of AOMinduced ACF and of colon cancer in rats (4) . With respect to retinoids, 4-HPR, 13-cis-RA and all-trans-RA have been reported to reduce the yield of ACF induced by AOM (20, 23) . All-trans-RA decreased the level of c-Myc and increased that of c-Fos in ACF, indicating that the retinoid influenced cell proliferation and differentiation in these lesion (23) . Reduction in cell proliferation and/or enhancement of differentiation have been proposed as mechanisms for chemopreventive agents, including retinoids, in the colon (5, 6, (29) (30) (31) (32) . Therefore, it would appear reasonable that the effect of retinoids on ACF could be used to rank their efficacy in preventing colon cancer. We find that the retinoids have the ability to prevent AOMinduced ACF and to reduce cell proliferation in ACF and noninvolved crypts of the colon of rats. Furthermore, a good correlation was observed between prevention of ACF and reduction of cell proliferation. Finally, we find that 9-cis-RA and 4-HPR can prevent colon tumors.
Materials and methods

Chemicals
The retinoids 2-, 3-and 4-(carboxyphenyl)retinamide (CPR), 2-, 3-and 4-HPR, 9-cis-RA, temarotene, RO 16-9100, N-(ethyl)-9-cis-retinamide (Et-9-cis-R), 4-(methoxyphenyl)retinamide (4-MPR) and 4-(ethoxyphenyl)retinamide (4-EPR) were obtained from the National Cancer Institute (Bethesda, MD). Retinol palmitate, AOM and tricaprylin were purchased from Sigma Chemical Co. (St Louis, MO) and AIN-76A diet from Dyets Inc. (Bethlehem, PA).
Animals
Male F344 rats were obtained at 6 weeks of age from the National Cancer Institute (Frederick, MD). They were housed and maintained in our AAALAC accredited laboratory animal facility in accordance with the US DHHS Guide for the Care and Use of Laboratory Animals. Solid-bottomed polycarbonate cages with stainless steel wire-bar lids and Bed-o-Cob bedding (Andersons, Toledo, OH) were used to house 2 rats/cage. The light cycle consisted of 12 h each of yellow light and dark. The animal rooms were maintained at 64-76°F and 55 Ϯ 15% relative humidity. Drinking water and diet were supplied to the animals ad libitum. Experimental design 1: prevention of ACF The retinoids were evaluated in four blocks with each containing three or four retinoids plus an AOM ϩ vehicle control group. The retinoids were evaluated at 1.0 and 2.0 mmol/kg diet when 3.0 mmol/kg was toxic or at 0.5 and 1.0 mmol/kg diet when 2.0 mmol/kg was toxic, except for 9-cis-RA, which was toxic at these concentrations. In a preliminary toxicity study rats exposed to 0.20 mmol/kg diet 9-cis-RA had a lower body weight during the third week of exposure and then recovered. Therefore, we evaluated 9-cis-RA at 0.10 mmol/kg diet. Block 1 consisted of 2-, 3-and 4-HPR at 391 (1.0 mmol/kg) and 782 (2.0 mmol/kg) mg/kg diet; Block 2 consisted of 2-, 3-and 4-CPR at 210 (0.5 mmol/kg) and 420 (1.0 mmol/kg) mg/kg diet and 9-cis-RA at 30 mg/kg (0.10 mmol/kg); Block 3 consisted of RO 16-9100 at 300 and 600 mg/kg and Et-9-cis-R at 326 and 652 mg/kg and temarotene at 304 and 608 mg/kg diet, representing 1.0 and 2.0 mmol/kg diet for each retinoid; Block 4 consisted of retinol palmitate at 263 and 525 mg/kg diet, 4-MPR at 203 and 405 mg/kg diet and 4-EPR at 210 and 419 mg/kg diet, representing 0.5 and 1.0 mmol/kg diet for each retinoid. The treatment groups contained nine or 10 animals each. The retinoids were dissolved in alcohol/tricaprylin (1:3, 40 ml/kg diet) vehicle before being mixed with AIN-76A powder diet. The control diet was mixed with vehicle only.
At 8 weeks of age the male F344 rats were randomly assigned to the treatment groups so that there was no significant difference in the starting body weights among the groups. Body weight was monitored weekly throughout the ACF experiments. After the animals were assigned to the treatment groups they started to receive the diet containing the retinoid or the vehicle, ad libitum. One week later the rats received the first of two weekly i.p. injections of 15 mg/kg body wt AOM in saline. The rats received injections of AOM between 9.00 and 11.00 in the morning. The animals continued to receive the retinoids in their diet for a total of 5 weeks, at which time they were killed by CO 2 asphyxiation.
At necropsy the animals were weighed and the colons removed from cecum to anus, flushed with 0.9% NaCl solution, slit open longitudinally, flattened between a piece of filter paper and plastic mesh, fixed in 70% alcohol and stored at 4°C. The colons were stained and evaluated for ACF as described by Bird (24) . Briefly, they were stained for 10 min in a solution of 0.2% methylene blue (Sigma Chemical Co.) dissolved in 70% alcohol, after which they were placed mucosal side up and with the aid of a light microscope (magnifications of 40ϫ and 100ϫ) evaluated for the presence of ACF. The criteria used to identify ACF included the following: (i) increased size of crypts; (ii) increased thickness of the epithelial cell lining; (iii) elongation of the luminal opening; (iv) increased pericryptal zone separating the crypts from surrounding normal appearing crypts. The number of ACF and their location in the colon were recorded along with the number of crypts in each foci.
Proliferating cell nuclear antigen (PCNA) staining
Colonic tissue in the distal 9-10 cm from anus was cut out from each colon and embedded in paraffin. Serial crosssections of 5 µm each were cut parallel to the mucosal surface and mounted onto gelatin-coated glass slides. The paraffin was removed with xylene and the tissue sections placed in 2 N HCl at 37°C for 30 min. Endogenous peroxidase was quenched by placing the tissue sections in 3% H 2 O 2 (Sigma Chemical Co.) for 30 min. The sections were blocked with diluted horse serum (Vector Laboratories) for 30 min and then incubated with 100 µl monoclonal mouse anti-PCNA (dilution 1:300; Sigma Chemical Co.) at room temperature for 1 h. The sections were washed and incubated with biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA) for 30 min at room temperature, followed by 30 min with Vectastain ABC reagent (Vector Laboratories). Staining was developed using 3,3Ј-diaminobenzidine tetrahydrochloride for 15 min. The slides were counterstained with hematoxylin. PCNA-containing nuclei stained brown while PCNA lacking nuclei were blue.
Measurement of cell proliferation
Only ACF with complete serial sections were selected for assessing the yield and distribution of PCNA-positive cells along the crypt height. The number of PCNA-labeled and unlabeled epithelial cells in the cross-sections of the crypts in an ACF and of non-involved crypts were recorded from the mouth to the base of crypts. The total number of cells in each crypt was calculated by adding the number of labeled and unlabeled cells. The PCNA labeling index was determined by dividing the number of PCNA-positive cells by the total number of cells in a cryptϫ100. The length of the crypt was determined by multiplying the total number of cross-sections containing it by 5 µm. The size of the proliferative compartment was the length from the base of the crypt to the section containing the last PCNA-positive cell divided by the total length of the cryptϫ100.
Experimental design 2: prevention of colon tumors
At 8 weeks of age male F344 rats were randomly divided into eight treatment groups so that there was no significant difference in the starting body weights among the groups. Treatment Groups 1-5 contained 36 rats and Groups 6-8 contained six rats each. After being assigned to the treatment groups the animals started to receive either 9-cis-RA, 4-HPR or the vehicle in their diet ad libitum. The concentrations of 9-cis-RA added to the diet were 0.1 mmol/ kg for the first 3 weeks followed by 0.2 mmol/kg for the remainder of the experiment (0.1-0.2 mmol/kg) and of 4-HPR were 1.0 (391 mg) and 2.0 (782 mg) mmol/kg diet. The 0.1-0.2 mmol/kg treatment schedule was used because in a preliminary study 0.2 mmol/kg only affected the body weight of the animals during the third week of exposure. One week after the start of exposure to the retinoids the rats in Groups 1-5 were administered the first of two weekly i.p. injections of 15 mg/kg body wt AOM each and those in Groups 6-8 received the vehicle, saline. The rats received injections of AOM between 9.00 and 11.00 in the morning. The animals continued to receive the retinoids in their diet for a total of 36 weeks, at which time they were killed by CO 2 asphyxiation. Body weight was monitored weekly for the first 6 weeks and monthly thereafter throughout the experiment.
At necropsy the animals were weighed and the colons removed from cecum to anus, flushed with 0.9% NaCl solution, slit open longitudinally and examined for tumors, which were harvested and fixed in 70% alcohol. The tumors were given a unique identification number and their size and locations recorded. After harvesting the tumors the colons were flattened between a piece of filter paper and plastic mesh, fixed in 70% alcohol and stored at 4°C. Colons from 10 randomly selected animals in Groups 1-5 were stained and evaluated for ACF by the procedure of Bird (24), as described above. The alcohol-fixed tumors were embedded in paraffin, sectioned and stained with hematoxylin and eosin for histopathological evaluation. Colon tumors were classified as adenomas or adenocarcinomas, using the classification described by Elwell and McConnell (34) . Tumors that did not exhibit invasion through the muscularis mucosa were classified as adenomas, while those with invasion across the line of the muscularis mucosa were adenocarcinomas.
Statistical analyses
The data was analyzed by an one-way ANOVA followed by comparison of pairs using the Bonferroni correction with P Ͻ 0.05 or 0.01 or by the Tukey test with a P Ͻ 0.05. SigmaStat v.2.0 software was used (Jandel Corp., San Rafael, CA).
Results
Prevention of ACF
The body weight of the animals was not affected by any of the 13 retinoids. The effect of the retinoids on the yield of ACF in the colon is presented in Table I , in which they are listed in descending activity at 1.0 mmol/kg diet. Hence, 2-CPR caused the greatest reduction in the yield of ACF (57.7%) and 4-CPR and Et-9-cis-RA did not exhibit significant activity. All the other retinoids when administered at 1.0 mmol/ kg diet were of intermediate activity, reducing the yield of ACF by 26.2-49.1%, except for 9-cis-RA, which was too toxic to be evaluated at this concentration. However, 9-cis-RA was active at a lower concentration (0.1 mmol/kg), reducing the yield of ACF by 41.6%. The effect of the retinoids upon the yield of ACF of different sizes as measured by the number of crypts/focus was determined and the results for the three CPRs are presented in Figure 1 . The results for the three CPRs are presented since they are representative of the other retinoids and because they cover the range of activity for the retinoids in preventing ACF, i.e. statistically inactive 4-CPR (22.4% reduction in ACF), moderately active 3-CPR (42.5% reduction) and most active 2-CPR (57.7% reduction). The three CPRs as well as the other retinoids, except for the inactive Et-9-cis-RA, preferentially reduced the yield of ACF containing a single crypt. 2-CPR also reduced the yield of ACF containing two crypts but not those with three or more crypts. The reduction in ACF with a single crypt was statistically significant for 4-CPR, even though its effect on the total yield of ACF was not statistically significant.
Cell proliferation in ACF and non-involved crypts.
The colons from the rats exposed to 1.0 mmol/kg diet of the three CPRs or 4-HPR and 0.1 mmol/kg diet 9-cis-RA were used to determine the relationship between prevention of ACF and modulation of cell proliferation. The three CPRs were chosen again because they cover the range of activity in preventing ACF and 4-HPR and 9-cis-RA because we evaluated them for the prevention of colon cancer. The PCNA labeling index, the size of the PCNA proliferative compartment and the number of cells/crypt in both ACF and non-involved crypts are presented in Table II . The ACF had approximately twice as many cells as non-involved crypts. None of the five retinoids altered the number of cells in either ACF or non-involved crypts. The PCNA labeling index and the size of the proliferative compartment were greater in ACF (39.6 Ϯ 2.8 and 85.7 (Table I) and PCNA labeling index (Table II) reduction in PCNA labeling index in ACF and in non-involved crypts are presented in Figure 2A and B respectively. A good correlation was indicated between the ability of the retinoids to prevent ACF and to decrease PCNA labeling index, especially in ACF. 2-CPR caused the greatest reduction in yield of ACF (57.7% reduction in ACF) and the lowest PCNA labeling index (24.9 Ϯ 2.1%) in ACF. 4-CPR did not significantly reduce either yield of ACF or PCNA labeling index in ACF, resulting in only a 20.1% reduction in ACF and a PCNA labeling index of 33.9 Ϯ 1.8%. 3-CPR, 4-HPR and 9-cis-RA were of similar ability in reducing both yield of ACF and PCNA labeling index. When the reduction in size of the proliferative compartment by the retinoids in either noninvolved crypts or ACF were compared with their prevention of ACF, the correlation was not as good.
Prevention of colon tumors
During the prevention of colon cancer study the body weight of rats was monitored weekly for the first 6 weeks and then 2122 monthly for the remainder of the study. Body weight was not affected by either 4-HPR or 9-cis-RA, deviating from the AOM control group by Ͻ7% at any time (only the high dose of 4-HPR varied this much). At the 36 week sacrifice the effect of 4-HPR and 9-cis-RA on yield of ACF and colon tumors is presented in Table III . 4-HPR reduced the yield of ACF by 47.8 and 47.1% and 9-cis-RA by 36.9 and 39.3% for their low and high concentrations respectively. In contrast to the results after 5 weeks exposure, when only ACF of a single crypt were reduced by 4-HPR and 9-cis-RA, after 36 weeks 4-HPR reduced the yield of foci of all three size classes, i.e. 1, 2 and ജ3 crypts, while 9-cis-RA reduced those containing 1 or 2 crypts but not ജ3 crypts (Figure 3 ). 4-HPR reduced the yield of colonic adenomas and adenocarcinomas per rat, while 9-cis-RA only significantly reduced the yield of adenomas (Table III) . The yield of total colon tumors (adenomas ϩ adenocarcinomas) was reduced by both retinoids. Similarly to the effect of the 
Discussion
Retinoids have been demonstrated to prevent cancer in liver, lung, mammary glands, prostate and skin of laboratory animals 2123 (11) (12) (13) (14) (15) (16) . Epidemiological studies have indicated an association between low dietary intake of vitamin A and development of colorectal cancer (7) . In rats 13-cis-RA has been reported to prevent 1,2-dimethylhydrazine (DMH)-induced colon cancer (11) but not colon cancer induced by intrarectally administered N-methyl-N-nitrosourea (MNU) (34) . Using these two models, four other retinoids, N-ethylretinamide, N-2-(hydoxyethyl)retinamide, 4-HPR and retinyl acetate, were either ineffective or inconsistent in preventing colon cancer (11, 35) . In the DMH model 2.0 mmol/kg 4-HPR reduced the number of rats with adenomas but not the number with adenocarcinomas, while in the MNU model it did not affect the incidence of rats with either tumor (35) . The body weights of the animals fed 4-HPR in these prior studies were as much as 12% lower than controls (11) . More recently, 4-HPR and 13-cis-RA have been reported to prevent AOM-induced ACF (20) , further suggesting that retinoids have chemopreventive activity in the colon. We therefore determined the ability of 4-HPR and 9-cis-RA to prevent AOM-induced colon cancer. Both 4-HPR and 9-cis-RA reduced the yield/rat of adenomas and the sum of adenomas ϩ adenocarcinomas, with 4-HPR also reducing the yield of adenocarcinomas/rat. The body weight of the animals administered AOM and the high concentration of 4-HPR (2.0 mmol/kg) differed by Ͻ7% from the animals administered AOM ϩ control diet. The body weights of the animals administered AOM and either the low concentration of 4-HPR (1.0 mmol/kg) or 9-cis-RA did not differ from AOM ϩ control diet-treated animals by Ͼ2%. Thus we demonstrated that these two retinoids can reduce the yield of AOM-induced colon tumors without affecting the body weights of the animals or exhibiting any visual evidence of toxicity. ACF have many characteristics in common with colon tumors, as reviewed by Bird (17) , hence, prevention of them has been used as an assay to screen agents for chemopreventive activity in the colon (4, (19) (20) (21) (22) (23) . We therefore used this assay to screen 11 retinoids in addition to 4-HPR and 9-cis-RA for the ability to prevent ACF and as an indication of their relative efficacy as potential chemopreventive agents in the colon. At 1.0 mmol/kg 2-CPR produced the greatest reduction in the yield of AOM-induced ACF (57.7% reduction in yield), suggesting that it will be the most active of the 13 retinoids, including 4-HPR and 9-cis-RA, in preventing colon cancer. Although the highest concentration of 2-CPR evaluated was 1.0 mmol/kg diet, it was more active in preventing ACF than the retinoids evaluated at 2.0 mmol/kg. The reduction in ACF by 4-HPR and 9-cis-RA varied from 31.6 to 40.3% and 36.9 to 47.8% at 4 and 35 weeks after the first dose of AOM respectively. Therefore, during continued exposure to the retinoids the extent of reduction in the yield of ACF was not changed. The maximum reduction in colon tumors resulting from exposure to either 4-HPR or 9-cis-RA was 56.0% by the high dose of 4-HPR (2.0 mmol/kg diet), which was also the most active of these two retinoids in preventing ACF. 2-CPR only slightly prevented more ACF than the high dose of 4-HPR (57.7 versus 48.1%). Therefore, the maximum prevention of colon tumors by 2-CPR is not expected to be much greater than the 56.0% obtained with 4-HPR at 2.0 mmol/kg diet. Hence, more complete prevention of ACF and colon cancer would appear to require either the development of a retinoid with a better margin of safety or the use of a combination of a retinoid with another chemopreventive agent.
Retinoids would appear to prevent ACF, and likely colon cancer, by both reducing cell proliferation and enhancing differentiation in them. All-trans-RA has been shown to decrease c-Myc and increase c-Fos in AOM-induced ACF (23) . A decrease in c-Myc and increase in c-Fos induced by RA have been associated with a decrease in cell proliferation and enhancement of differentiation respectively (39) (40) (41) . Therefore, the differing effects of all-trans-RA on the two proto-oncogenes in ACF would support the proposal that retinoids reduce cell proliferation and enhance differentiation in ACF. We used two measures of cell proliferation in ACF to determine the effect of retinoids, i.e. PCNA labeling index and size of the proliferative compartment. In humans an increase in the size of the proliferative compartment has been associated with an increased risk for colorectal cancer (28) (29) (30) , while the labeling index of low risk controls did not differ from familial polyposis patients (28, 29, 37, 38) . Hence, in humans an increase in the size of the proliferative compartment would appear to be the better measurement of the two for increased risk of colon cancer. We found a better correlation of the ability of retinoids to prevent occurrence of ACF with their ability to reduce PCNA labeling index in ACF than with their reduction in the size of the proliferative compartment in ACF in rats. This correlation would suggest the use in rats of the PCNA labeling index in ACF as a marker for retinoidinduced reduction in cell proliferation and to rank the efficacy of retinoids in the colon.
The yield of AOM-induced colon ACF and tumors and the extent of cell proliferation in the ACF were reduced to a similar extent by 9-cis-RA and 4-HPR, albeit at different dose levels. However, these retinoids have been proposed to operate by different mechanisms (42-44). 9-cis-RA has been shown to directly interact with the known RA receptors and retinoid X receptors (42) , while it has been suggested that 4-HPR acts by a unique pathway that is not mediated by these retinoid receptors (43, 44) . Our results of similar reductions induced by 9-cis-RA and 4-HPR in the level of cell proliferation, the yield of ACF and the yield of colon tumors would suggest a common mechanism for the two retinoids.
